2-year disease-free survival rate
Showing 1 - 25 of >10,000
Prostate Cancer, Node; Prostate, Radiotherapy Side Effect Trial in Quebec (Report and compare changes in a non-inferiority
Recruiting
- Prostate Cancer
- +2 more
- Report and compare changes in a non-inferiority analysis of the International Prostate Symptom Score (I-PSS)
- +7 more
-
Quebec, CanadaCHUdeQuebec
Apr 7, 2023
Bladder Cancer, Bladder Urothelial Carcinoma Trial in Toronto (re-TURBT, 6 weeks BCG instillation)
Terminated
- Bladder Cancer
- Bladder Urothelial Carcinoma
- re-TURBT
- 6 weeks BCG instillation
-
Toronto, Ontario, CanadaUniversity Health Network
Apr 12, 2022
Breast Tumors Trial in Saint Louis (Doxorubicin, Trastuzumab, Cyclophosphamide)
Terminated
- Breast Neoplasms
- Doxorubicin
- +7 more
-
Saint Louis, MissouriWashington University School of Medicine
Oct 31, 2022
Dupuytren's Disease Trial in Mulhouse, Pessac (Aponeurectomy with grafting, Aponeurectomy alone)
Recruiting
- Dupuytren's Disease
- Aponeurectomy with grafting
- Aponeurectomy alone
-
Mulhouse, France
- +1 more
Aug 4, 2022
Survival in Adult MRD Positive Acute Lymphoblastic Leukemia
Completed
- Acute Lymphoblastic Leukemia
-
Brno, Czechia
- +9 more
Sep 12, 2022
Rectal Cancer Trial in United States (drug, radiation, behavioral, procedure)
Active, not recruiting
- Rectal Cancer
- Oxaliplatin (OXAL)
- +6 more
-
Irvine, California
- +25 more
Jan 12, 2023
Primary Non-metastatic Breast Cancer, Who Remain Disease-free Trial in Lyon, Villejuif (Everolimus, Placebo)
Active, not recruiting
- Primary Non-metastatic Breast Cancer
- Who Remain Disease-free
- Everolimus
- Placebo
-
Lyon, France
- +1 more
Feb 23, 2022
Liver Transplant; Complications, Hepatocarcinoma, Recurrent Osteosarcoma Trial in Beijing (multi-kinase inhibitors in
Not yet recruiting
- Liver Transplant; Complications
- +3 more
- multi-kinase inhibitors in combination with bevacizumab
-
Beijing, Beijing, ChinaChinese Academy of Medical Sciences & Peking Union Medical Colle
Sep 11, 2023
Hepatocellular Carcinoma Trial in Nanjing (cTACE, Dicycloplatin (TP21), Epirubicin)
Recruiting
- Hepatocellular Carcinoma
- cTACE
- +2 more
-
Nanjing, Jiangsu, ChinaZhongda Hospital, Southeast University
Jul 22, 2022
Recurrent Cervical Carcinoma, Radiotherapy, Epidermal Growth Factor Receptor Trial in Beijing (Combination of nimotuzumab and
Recruiting
- Recurrent Cervical Carcinoma
- +6 more
- Combination of nimotuzumab and radiotherapy
-
Beijing, Beijing, ChinaLei Li
Dec 18, 2020
Colorectal Cancer Metastatic Trial in Guangzhou (Fruquintinib)
Recruiting
- Colorectal Cancer Metastatic
-
Guangzhou, Guangdong, ChinaColorectal Department,SunYat-sen University Cancer Center
Aug 28, 2023
Lymph Node Metastasis, Cancer of Rectum and Anus, Oxaliplatin Trial in Beijing (Experimental: FOLFOXIRI and Lateral lymph node
Enrolling by invitation
- Lymph Node Metastasis
- +6 more
- Experimental: FOLFOXIRI and Lateral lymph node dissection
- Preoperative long-term concurrent chemoradiotherapy and Lateral lymph node dissection
-
Beijing, Beijing, ChinaCancer Hospital, Chinese Academy of Medical Sciences, Peking Uni
Sep 15, 2023
Gastric Cancer, Nutrition Related Cancer, Sarcopenia Trial (Exercise Intervention, Nutrition Intervention)
Not yet recruiting
- Gastric Cancer
- +2 more
- Exercise Intervention
- Nutrition Intervention
- (no location specified)
Jul 17, 2023
Esophageal Squamous Cell Carcinoma Trial in Hanzhou, Ningbo (Neoadjuvant Radiotherapy, Neoadjuvant Chemotherapy, Immunotherapy)
Recruiting
- Esophageal Squamous Cell Carcinoma
- Neoadjuvant Radiotherapy
- +2 more
-
Hanzhou, Zhejiang, China
- +2 more
Aug 16, 2022
Gastric, Colorectal Adenocarcinoma Trial in Shenyang (tislelizumab)
Not yet recruiting
- Gastric
- Colorectal Adenocarcinoma
-
Shenyang, Liaoning, ChinaLiaoning Cancer Hospital & Institute
Nov 1, 2023
Neoadjuvant Pembrolizumab in III-IVA Resectable Oral Squamous
Recruiting
- Oral Cavity Squamous Cell Carcinoma
-
Guangzhou, Guangdong, ChinaLiuxiqiang
Feb 1, 2023
Squamous Cell Carcinoma of Head and Neck, Neoadjuvant Therapy, Resection Margin Trial in Wuhan (Reducing Excision Margins)
Active, not recruiting
- Squamous Cell Carcinoma of Head and Neck
- +2 more
- Reducing Excision Margins
-
Wuhan, Hubei, ChinaZhanjie Zhang
Jul 11, 2022
Adult Acute Myeloid Leukemia Trial in Beijing (microtransplantation, HLA-mismatched donor peripheral stem cell infusion,
Recruiting
- Adult Acute Myeloid Leukemia
- microtransplantation, HLA-mismatched donor peripheral stem cell infusion
- +2 more
-
Beijing, Beijing, ChinaThe fifth medical center of PLA General Hospital
Feb 21, 2022
Locally Advanced Esophageal Squamous Cell Carcinoma Trial (Tiragolumab)
Not yet recruiting
- Locally Advanced Esophageal Squamous Cell Carcinoma
- (no location specified)
Feb 23, 2023
Multiple Myeloma Trial in Augusta (Lenalidomide, Vitamin D - Intensified, Vitamin D - Therapeutic)
Not yet recruiting
- Multiple Myeloma
- Lenalidomide
- +2 more
-
Augusta, GeorgiaGeorgia Cancer Center at Augusta University
Apr 26, 2023
Colon Cancer Liver Metastases Trial (sequential adult left lateral lobe liver transplantation (SALT))
Not yet recruiting
- Colon Cancer Liver Metastases
- sequential adult left lateral lobe liver transplantation (SALT)
- (no location specified)
Oct 3, 2023
Breast Cancer Trial in Shanghai (Regional lymph node radiotherapy, chest/whole breast irradiation)
Recruiting
- Breast Cancer
- Regional lymph node radiotherapy
- chest/whole breast irradiation
-
Shanghai, Shanghai, ChinaRuijin Hospital, Shanghai jiaotong univestigy school of medicine
Aug 3, 2023
Long-term Survival and Quality of Life After Minimally Invasive
Not yet recruiting
- Esophagus Cancer
- +3 more
-
Ji'nan, Shandong, ChinaQilu Hospital of Shandong University
Nov 19, 2023
Stereotactic Radiotherapy on Metastatic Spinal Tumors Using
Not yet recruiting
- Spinal Bone Metastases
- Radiation Therapy
- Stereotactic body radiotherapy
- (no location specified)
Apr 11, 2023